ZTI-01

DRUG3 trials

Conditions

Acute PyelonephritisCardiac Repolarization in Healthy SubjectsHealthy Lactating WomenUrinary Tract Infection ComplicatedUrinary Tract Infection Symptomatic

Phase 1

4-way Crossover QT Evaluation in Healthy Subjects

CompletedNCT03709927

Nabriva Therapeutics AGCardiac Repolarization in Healthy Subjects

Start: 2018-01-11End: 2018-08-21Updated: 2019-03-06

Phase 2

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

CompletedNCT02753946

Nabriva Therapeutics AGAcute Pyelonephritis, Urinary Tract Infection Complicated, Urinary Tract Infection Symptomatic

Start: 2016-04-30End: 2017-05-30Updated: 2019-03-07

Phase 4

Evaluation of the Excretion of Fosfomycin Into Breast Milk Following a Single Intravenous Dose of ZTI-01 (6 g) in Healthy Lactating Women

Not yet recruitingNCT07618299

Meitheal Pharmaceuticals, Inc.Healthy Lactating Women

Start: 2026-07-01End: 2027-08-01Target: 24Updated: 2026-06-01

Related Papers

Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial

Clinical Infectious Diseases2019-02-28134 citations

Population Pharmacokinetic (PPK) Analysis of ZTI-01 (Fosfomycin for Injection) Using Data from Healthy Subjects and Patients with Complicated Urinary Tract Infections (cUTI)